En-tête de navigationNavigation principaleSuiviFiche


Unité de recherche
PCRD EU
Numéro de projet
02.0257
Titre du projet
STEMGENOS: Engineered mesenchymal stem cells combined with gene therapy for osteoarticular disease
Titre du projet anglais
STEMGENOS: Engineered mesenchymal stem cells combined with gene therapy for osteoarticular disease

Textes relatifs à ce projet

 AllemandFrançaisItalienAnglais
Mots-clé
-
-
-
Anzeigen
Autre Numéro de projet
-
-
-
Anzeigen
Programme de recherche
-
-
-
Anzeigen
Description succincte
-
-
-
Anzeigen
Résumé des résultats (Abstract)
-
-
-
Anzeigen
Références bases de données
-
-
-
Anzeigen

Textes saisis


CatégorieTexte
Mots-clé
(Anglais)
Biotechnology; Environmental Protection; Innovation; Technology Transfer; Life Sciences; Medicine; Health; Waste Management
Autre Numéro de projet
(Anglais)
EU project number: QLK3-CT-2002-02039
Programme de recherche
(Anglais)
EU-programme: 5. Frame Research Programme - 1.1.3 The 'cell factory'
Description succincte
(Anglais)
See abstract
Résumé des résultats (Abstract)
(Anglais)
Destruction of articular cartilage occurs in rheumatoid arthritis (RA) and osteoarthritis (OA) having an incidence of 1 % and 12% in the population respectively. The resulting disabilities of RA and OA have a major impact on the European economy and health. The novel immuno therapies available have a serious limitation as only targets the inflammatory process, which returns when therapy ceases and does not cure damaged cartilage.

Our hypothesis is: Restoration of joint function could be achieved by long term therapy that is both anti-inflammatory and provides for cartilage differentiation factors that facilitate and induce tissue repair using genetically engineered mesenchymal stem cells (MSC). We will genetically engineer mouse and human MSC using transcriptionally regulated lenti-viral vectors. These cells will attach to damaged cartilage and synthetic matrices, express chondrogenic differentiation or transcription factors and immunosuppressive compounds to enable long term tissue repair in OA and RA. Engineered cells will be assessed in vitro and in vivo in models of RA and OA. This project will deliver new therapeutics in form of nucleic acids, proteins and engineered cells. These novel technologies would be exploited commercially.
Références bases de données
(Anglais)
Swiss Database: Euro-DB of the
State Secretariat for Education and Research
Hallwylstrasse 4
CH-3003 Berne, Switzerland
Tel. +41 31 322 74 82
Swiss Project-Number: 02.0257